Table 1:
Baseline Patient and Tumor Characteristics
| Characteristic | BCLC B + C (n = 494) | BCLC B (n = 123) | BCLC C (n = 371) |
|---|---|---|---|
|
| |||
| Age (y)* | 62 (56–71) | 62 (57–71) | 60 (55–71) |
| Sex | |||
| M | 401 (81.2) | 108 (87.8) | 293 (79.0) |
| F | 93 (18.8) | 15 (12.2) | 78 (21.0) |
| Race or ethnicity | |||
| African American | 98 (19.8) | 26 (21.1) | 72 (19.4) |
| Asian | 36 (7.3) | 7 (5.7) | 29 (7.8) |
| Caucasian | 311 (63.0) | 82 (66.7) | 229 (61.7) |
| Hispanic | 8 (1.6) | 0 | 8 (2.2) |
| Other† | 41 (8.2) | 8 (6.5) | 33 (8.9) |
| Cause of cancer | |||
| Hepatitis B virus | 77 (15.6) | 19 (15.4) | 58 (15.6) |
| Hepatitis C virus | 242 (49.0) | 67 (54.5) | 175 (47.2) |
| Alcohol use disorder | 150 (30.4) | 25 (20.5) | 125 (33.7) |
| Cirrhosis | 278 (56.3) | 76 (61.8) | 202 (54.4) |
| Nonalcoholic steatohepatitis | 38 (7.7) | 13 (10.6) | 25 (6.7) |
| Cryptogenic | 24 (4.9) | 7 (5.7) | 17 (4.6) |
| α-fetoprotein level | |||
| <400 ng/mL | 183 (37.0) | 58 (47.2) | 125 (33.7) |
| ≥400 ng/mL | 96 (19.4) | 18 (14.6) | 78 (21.0) |
| ECOG performance status | |||
| 0 | 205 (41.5) | 123 (100) | 82 (22.1) |
| 1 | 267 (54.0) | 0 | 267 (72.0) |
| 2 | 22 (4.5) | 0 | 22 (5.9) |
| Child-Pugh class | |||
| A | 309 (62.6) | 95 (77.2) | 214 (57.7) |
| B | 185 (37.4) | 28 (22.8) | 157 (42.3) |
| Embolization type | |||
| DEB-TACE | 202 (40.9) | 48 (39.0) | 154 (41.5) |
| Lipiodol | 292 (59.1) | 75 (61.0) | 217 (58.5) |
| Sorafenib administered after TACE | 129 (26.1) | 34 (27.6) | 95 (25.6) |
| Liver volume (cm3)* | 1948 (1500–2544) | 1842 (1517–2372) | 1992 (1484–2611) |
| Tumor characteristics | |||
| Tumor multiplicity | |||
| Unifocal | 94 (19.0) | 0 | 94 (25.3) |
| Multifocal | 400 (81.0) | 123 (100) | 277 (74.7) |
| Extrahepatic metastasis | 74 (15.0) | 0 | 74 (19.9) |
| Portal vein invasion | 170 (34.4) | 0 | 170 (45.8) |
| Total tumor volume (cm3)* | 224 (64–818) | 139 (63–353) | 294 (67–928) |
| Median ETV (cm3)* | 94 (26–366) | 57 (25–165) | 130 (27–429) |
| Median ETB (%)* | 5 (1–16) | 4 (1–9) | 7 (2–20) |
Note.—Unless otherwise specified, data are numbers of patients, with percentages in parentheses. BCLC = Barcelona Clinic Liver Cancer, DEB = drug-eluting bead, ECOG = Eastern Cooperative Oncology Group, ETB = enhancing tumor burden, ETV = enhancing tumor volume, TACE = transarterial chemoembolization.
*
Data are medians, with IQRs in parentheses.
†
“Other” included individuals who identified as Middle Easterner/Arabic, Indian, non-Hispanic Latino, or South American individuals of mixed race.